DAX
18.163,52 -90,66 (-0,50%) Euro Stoxx 50
4.907,30 -40,43 (-0,82%) Dow Jones 30
39.150,33 +15,57 (+0,04%) Gold
2.334,70 -34,30 (-1,45%) EUR/USD
1,0697 -0,0009 (-0,09%) Bitcoin EUR
60.263,55 +158,10 (+0,26%)
Acumen Pharmaceuticals, Inc. (ABOS)
Nachbörse:
Acumen Pharmaceuticals, Inc.
427 Park Street
Charlottesville, VA 22902
United States
434 297 1000
https://acumenpharm.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 51
Beschreibung
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Corporate Governance
Acumen Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 6, Shareholderrechte: 8, Kompensation: 9.
